Replimune Group, Inc. is subject to a securities class action lawsuit alleging it failed to disclose that its RP1 trial designs did not address FDA study-design concerns. The lawsuit covers shareholders who bought shares between October 2025 and April 2026, during which the stock price dropped about 84% after the FDA rejected the RP1 biologics license application. Institutional investors with significant losses are encouraged to consider lead plaintiff roles. The case highlights potential regulatory and disclosure issues that affected investor confidence and share value.
The Lovesac Company reported a better-than-expected Q2 earnings per share (EPS) of -$0.35, beating estimates by over 10% and improving from a -$0.45 loss a year ago. Despite this EPS beat, the company's revenue of $161.25 million narrowly missed anal...
Copart, Inc. is set to report its Q3 earnings with analysts expecting an EPS of $0.38, down from $0.41 last year, while revenue is projected to increase slightly to $1.14 billion from $1.13 billion. The company faces headwinds from a weak US market a...
Agree Realty Director Rakolta has purchased 20,136 shares of the company, investing approximately $1.5 million. This insider buying could signal confidence in the company's future prospects. Investors may view this as a positive sign, potentially imp...
MasterCraft Boat Holdings reported Q4 earnings of $0.67 per share, surpassing analyst estimates of $0.61 and up from $0.40 a year ago. Revenue reached $129.94 million, well above the expected $93.05 million. The company maintains a strong current rat...
RH is set to report Q2 2026 earnings facing challenges from a weak housing market and international expansion expenses. Analysts expect earnings per share to fall significantly to between $0.38 and $0.46, down from $2.93 last year, despite a slight r...
